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A variety of cells known to be involved in acute inflammatory reactions (mast cells 
and basophils, neutrophils, platelets, and macrophages) respond to the anaphylatoxic 
polypeptides C4a,  C3a,  or C5a with  secretion  of biogenic  amines  and  secretion  of 
various  enzymes  (1-11).  These  biological  activities  of anaphylatoxic  complement 
fragments were studied mainly in vitro by use of purified or even synthetic substances 
(12-17). 
Calculations from experiments (18)  performed in a  recently developed guinea pig 
platelet system led to the conclusion  that  cleavage of <1%  of the serum C3 or C5, 
leading  to  generation  of C3a  and  C5a,  could  induce  a  marked  release  of platelet 
granule constituents. Sufficient amountsof anaphylatoxins may physiologically occur 
by the attack of various enzymes on C3 or C5 in the circulation or at a local site. Such 
high levels of activity require efficient control mechanisms. 
Investigations (19-21)  with serum provided evidence for control mechanisms rep- 
resented  by humoral  factors such  as carboxypeptidases or proteases, which  rapidly 
destroy  the  biologic  activity  of anaphylatoxins  once  they  are  generated  from  the 
native complement components. However, anaphylatoxin activity can be detected in 
vivo in several species (22,  23)  in spite of fluid-phase regulatory mechanisms. Besides 
these  humoral  factors,  a  regulatory  phenomenon  on  the  target  cell  level has been 
observed (3, 24, 25) : after incubation of cells with an anaphylatoxic stimulus, they do 
not respond a  second time to the same or a  related stimulus.  Desensitization turned 
out  to be stimulus specific. In addition,  desensitization  could be achieved with  low 
amounts of stimulating substances that were lower than those required  to lead to a 
detectable release reaction (18). 
The experiments described in this study were performed to provide information on 
how  cell  reactivity  to  anaphylatoxic  stimuli  is  influenced  by  the  phenomenon  of 
specific desensitization. 
We were especially interested in investigating how platelets respond to an anaphy- 
latoxic stimulus generated in their presence, which seems more likely to happen under 
in vivo conditions than from exposure to preformed anaphylatoxic molecules. 
For these investigations,  the platelet  system was chosen  because platelets can be 
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obtained  in  high  purity,  they  represent  very sensitive  targets,  and  they  offer the 
possibility of exact quantitation of biological anaphylatoxin activity (11,  18). 
Materials and Methods 
Chemicals.  Imipramine, a~ueous solution  (2 mg/ml), was obtained from (2iba Geigy, Basel, 
Switzerland.  Aquasol  and  [ H]serotonin  (NET  398,  1 m(2i/ml)  were obtained  from NEN- 
Chemicals, Dreieich Germany. 
Guinea Pig C5,  Guinea Pig CSa, and Guinea Pig C3a.  These were prepared according to the 
procedure described  by Meuer et al.  (18, 26). Specific activity of the C5-preparation was 2.0 
×  10  z3 site forming units/mg. 
Synthetic Hexapeptide C3a 72-77.  This was synthesized  according to a previously described 
method (17) by Dr. Andreatta (Research Department Pharmaceuticals Division,  Ciba Geigy, 
Basel, Switzerland). 
Cobra Venom Factor-C3 Convertase (VF-Bb).  This was generated by incubating purified cobra 
venom factor (VF) (27) with factors B (28) and D (29) of guinea pig complement in the presence 
of Mg  ÷+ and was purified as described (30). A 1:10 dilution of the particular preparation used 
led to a loss of 90% of hemolytic activity of guinea pig (25 (20 #g/ml) within 60 min at 37°C. 
Hemolytic C5 Assay.  This was performed as described  (31). 
Preparation of [~H]Serotonin-labeled Platelets and the [zH]Serotonin Release Assay.  These were 
performed as described (18). Calculations were performed as follows: 
percent specific release  cpm (test sample) -  cpm (buffer control) 
----  X  100. 
cpm (total label)  -  cpm (buffer control) 
Results 
Purified guinea pig C5 (final concentration 20 #g/ml) was incubated with minute 
amounts of the purified alternative pathway enzyme VF-Bb for 5,  15, and 25 min at 
37°C  in  the  absence  of  target  cells.  After  these  various  incubation  periods, 
[3H]serotonin-labeled  platelets  were  added  to  the  samples  and  incubated  for  an 
additional  5 min at 37°C.  Depending on the time of the first incubation,  increasing 
amounts  of anaphylatoxin  activity  co.uld  be  detected  in  the  incubation  mixture, 
measured as release of [nH]serotonin (Fig.  1). 
In a hemolytic test that was run parallel, no C5 turnover was observed, indicating 
a high sensitivity of the guinea pig platelet assay for detecting C5 cleavage. 
However,  when  amounts  of  C5  and  VF-Bb  equal  to  those  used  in  the  first 
experiment were incubated in the presence of [3H]serotonin-labeled platelets for 5, 15, 
and 25 min at 37°C, no release of the biogenic amine could be detected during the 
whole incubation period. The supernatants of these samples induced a strong release 
reaction, similar to that  described  above, when added  to fresh 3H-labeled platelets, 
indicating that high amounts of anaphylatoxin had been generated and maintained 
their activity. Controls with C5 in the absence of VF-Bb or with VF-Bb alone were 
negative. 
To determine whether low amounts of freshly generated C5a might have desensi- 
tized  the  platelets  to  higher  C5a  concentrations  appearing  subsequently  in  the 
incubation  mixture, the characteristics of the desensitization phenomenon were also 
investigated with purified C5a. 
Platelets were incubated with various amounts of C5a for 5 min at 37°C, followed 
by determination of [3H]serotonin release. Fig.  2 A  demonstrates the described dose 
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Fla.  1.  Influence of time on platelet reactivity against C5a generated in their absence or presence. 
A, C5  (20/~g/ml)  +  VF-Bb  (1:80)  were  incubated  for  various times at  37°C.  Then SH-labeled 
platelets were added and incubated for additional  5  min at  37°C, followed by determination of 
serotonin release. O, C5 (20 #g/ml) plus VF-Bb (1:80) were incubated for various times at 37°C in 
the presence of all-labeled platelets, followed by determination of serotonin-release. 
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Fro.  2.  Platelet reactivity against varying doses of purified C5a given as first and second stimulus. 
(A) 0,  platelets were incubated with  various doses of guinea pig CSa  (molarities shown on the 
abscissa) for 5 rain 37°C. Then PBS was added to each sample and incubated for additional 5 rain 
at 37°C, followed by determination of serotonin release. 03) O, platelets were incubated with various 
doses of guinea pig C5a (molarities shown on the abscissa) for 5 min at 37°C. Then guinea pig C5a 
(1.5  ×  10  -9  mol/liter)  was  added  and  incubated  for  additional  5  min  at  37°C,  followed  by 
determination of [3H]serotonin release. Fig. 2 B shows the additional release induced by the second 
stimulus (additional release is the total release minus release of first stimulus, see Fig.  2 A). The 
dotted line shows the release induced by the second stimulus alone (C5a 1.5 ×  10  -s mol/liter). 
To examine  the  desensitizing potency of C5a,  platelets  were  incubated with  the 
same amounts of C5a for 5 min at 37°C, as above. Then a  high dose of C5a (1.5  × 
10  -9 mol/liter), which alone would induce ~50% specific release (see dotted line Fig. 
2 B),  was added to all the test samples. After incubation for an additional 5 min at 
37°C,  the  total  [aH]serotonin  release  was  measured.  Fig.  2 B  demonstrates  that S.  MEUER, B. ZANKER, U.  HADDING, AND D. BITTER-SUERMANN  701 
preincubation with CSa negatively influenced platelet reactivity against a second C5a 
stimulus. In this figure, only the additional release mediated by the second stimulus 
is plotted  (see legend to Fig.  2).  Whatever concentration of C5a was used above 1.5 
×  10  -1° tool/liter in the first step, there was no additional release upon addition of a 
high  dose  of C5a  (1.5  ×  10  -9  mol/liter).  This  means  the  response  to  the  second 
stimulus was completely inhibited.  Below the level of 1.5  ×  10  -l° tool/liter, desensi- 
tization of the platelets to the second C5a stimulus could still be observed, even at 
concentrations of CSa, which did not lead to a  detectable release alone. Desensitiza- 
tion, however, was no longer complete. 
In a control experiment, platelets were washed after the first incubation period and 
then exposed to a second C5a stimulus. The results were the same as described above. 
Therefore,  for  practical  reasons,  a  washing  procedure  was  usually  omitted.  The 
stimulus specificity of desensitization was controlled by an unaltered response of the 
platelets to guinea pig C3a. 
In a next series of experiments, we tried to discover conditions under which platelets 
could respond to an anaphylatoxic C5a stimulus generated in their presence. 
Constant  amounts  of C5  (20  /lg/ml)  were  incubated  with  various  doses  of the 
enzyme VF-Bb (1 : 1500,  1:500, 1:100, 1:9) together with [aH]serotonin-labeled platelets 
for  5  min  at  37°C,  and  then  the  release  was  measured  (Table  I,  first  column). 
Additionally,  the response of guinea pig platelets after this  first incubation  step to 
purified C5a (3 ×  10  -9 mol/liter) as a second stimulus was determined in the various 
samples  (Table  I,  3rd  column).  Table  I,  2nd  column,  shows  the  amount  of C5a 
generated from C5 in the absence ofplatelets. The amount of C5a generated from C5 
by VF-Bb  was  the  same  whether  or  not  platelets  were  present  in  the  incubation 
mixture. 
The responsiveness of the platelets to C5a depended on the speed and the amount 
of C5a-generation  from C5,  which  was  a  function  of the  concentration  of VF-Bb 
applicated. The more enzyme VF-Bb was present, the more C5a was generated, and 
thus the degree of platelet response to a second C5a stimulus decreased as a result of 
desensitization induced during the first incubation step. C5 cleavage in the presence 
of the target cells led to platelet secretion only if a high concentration of the enzyme 
VF-Bb was used--conditions under which high amounts of C5a were rapidly gener- 
ated  (Table I,  1st  column).  Under these experimental conditions,  10.4%  of C5  had 
been cleaved after 5 min, as calculated by loss of hemolytic C5-activity. 
If this interpretation is correct, it should be possible to desensitize platelets to high 
concentrations of an anaphylatoxic stimulus by previously adding stepwise increasing 
amounts of a  related stimulus. Thereby, a state of stimulus-specific unresponsiveness 
could be induced without any preceeding secretory event. 
In the next experiments, we investigated platelet reactivity to C3a after pretreat- 
ment with a synthetic C3a-related hexapeptide comprising the amino acids 72-77 of 
human C3a  (His-Leu-Gly-Leu-Ala-Arg). This substance has been described  (17)  as 
inducing  platelet  secretion  and  desensitization  qualitatively  like  the  natural  C3a 
molecule. 
Platelets  were  treated  with  increasing  concentrations  of the  hexapeptide.  These 
various doses were added stepwise  in  2-rain  intervals to the samples.  At each step, 
platelet reactivity to an optimum dose of C3a (1.1 ×  10  -7 mol/liter) as second stimulus 
was determined. 702  CELLULAR CONTROL OF ANAPHYLATOXIN ACTIVITY 
TABLE  I 
Platelet Activation and Desensitization When C5a  Was Generated 
in Their Presence 
Specific release 
Platelets  Platelets  Platelets present dur- 
present  added after  ing C5a generation, 
during C5a  CSa  then addition of C5a 
as second stimulus 
generation  generation  (3.0 ×  10  -a tool/liter) 
% 
Guinea pig C5"  0  0  58.6 
0.9% NaCI 
0.9% NaCI  0  0 
VF-Bb (1:9):~ 
56.5 
Guinea pig C5  0  0  60.2 
VF-Bb (1:1,500) 
Guinea pig C5  0  0  21.8 
VF-Bb (1:500) 
Guinea pig C5  0  18.6 
VF-Bb (1:100) 
Guinea pig C5  46.2  53.2  45.7§ 
VF-Bb (1:9) 
The samples  of C5 and VF-Bb were incubated  for 5 min at 37°C. When 
platelets were present during this incubation period, release was measured 
after this time (first column). When platelets were absent  during the first 
incubation period, platelets were added after 5 rain at 37°C and incubated 
for an additional 5 min at 37°C (second column). If desensitization  to C5a 
should be measured,  C5a  (3.0 ×  10  -g mol/liter) was  added after the first 
incubation period (platelets  present)  and incubated for an additional 5 min 
at 37°C (third column). 
* Final concentration of C5 was always 20 pg/ml. 
Final dilutions of VF-Bb. 
§ This amount of [aH]serotonin  had been released  during the first incubation 
period (compare first column). 
The initial concentration of the hexapeptide in the sample was 6.4 ×  10  -s mol/liter 
and was increased to 3.1  ×  10  -7 mol/liter in the second step. It was further increased 
to  1.3  x  10  -6  mol/liter,  5.6  ×  10  -6  mol/liter,  and  2  ×  10  -5  tool/liter.  Finally  a 
concentration  of 7.9 x  10  -s mol/liter was reached. 
Fig.  3  demonstrates  that  when  the  concentration  of hexapeptide  was  increased 
stepwise, no release of [3H]serotonin  occurred.  As expected  (17),  the same concentra- 
tions of the hexapeptide,  if added  in a  single dose, led to secretion. 
Analogously to Fig.  2 B, where C5a was added  in an optimum  dose after pretreat- 
ment, platelet response  to C3a as additional  stimulus was also measured  (not  shown 
in Fig.  3).  The degree of desensitization  of the platelets pretreated  with low doses of 
hexapeptide (below 3.1 ×  10  -7 tool/liter) was identical whether the synthetic substance 
was applicated  in a  single dose or accumulated  stepwise.  With  increasing concentra- S.  MEUER,  B.  ZANKER,  U.  HADDING,  AND  D.  BITFER-SUERMANN 
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FIG.  3.  Influence of ~,~,)ted  vs. single doses of a synthetic hexapeptide on plateiet reactivity. O, 
dose-response curve of [ H]serotonin release from guinea pig platelets by the synthetic hexapeptide 
C3a 72-77. The various concentrations were added as single doses to the platelets. 0, [SH]serotonin 
release from guinea pig platelets when the various doses of C3a 72-77 were accumulated stepwise 
in 2-min intervals in the presence of the target cells. 
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FIG. 4.  Kinetics and close dependence of desensitization by hexapeptide at 37°C. The abscissa 
indicates the time at which the second high dose of hexapcptide (3.38 X  10  -6 tool/liter) was given 
to p]atelets that were pretrcated (time 0)  with difercnt  low concentrations of hexapcptide (first 
stimulus). After addition of the high dose, al] samples were incubated for a further 5 rain at 37°C. 
O,  [SH]serotonin release by four different, low doses of hexapeptide alone (first  stimulus). 
[3H]serotonin  release by the high dose of hexapeptide  alone  (second stimulus).  O,  [3H]serotonin 
release by the first plus second stimuli. 
tions of C3a 72-77, desensitization  increased as well. Above a  concentration of 3  X 
10  -7 mol/liter, a total unresponsiveness for C3a was achieved. 
Next we looked for the kinetics of desensitization and for approaches to dissociate 
the process of deactivation from the events leading to secretion.  Figs.  4  and 5 yield 
further information on the interdependence of both processes. In Fig. 4, the first low 
dose of hexapeptide  (1.35  X  10  -7  mol/liter  up  to  5.4  X  10  -7  mol/liter)  does  not 
mediate a release reaction, whereas a concentration of 1.35  X  10  -e tool/liter allows a 
mild release. The release mediated by this and by the second, high dose alone (3.38 
X  10  -5 mol/liter) is complete within 5 s at 37°C  (data not shown in Fig. 4). lax)king 704  CELLULAR CONTROL OF ANAPHYLATOXIN ACTIVITY 
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Fro.  5.  Kinetics  of desensitization  by  hexapeptide  at  22°C.  Abscissa,  same  as  in  Fig.  4.  C), 
[3H]serotonin release by the first, low dose of hexapeptide (1.35 X 10  -6 tool/liter) alone. - - -, as in 
Fig. 4. &, [aH]serotonin  release by the second, high dose of hexapeptide given at timed intervals to 
the pretreated platelets (with the first stimulus).  The closed symbols represent a parallel experiment 
done at 37°C. Q, first stimulus;  &, first plus second stimulus;  I, second stimulus. 
TABLE  II 
Kinetics of Desensitization to Hexapeptide in the Absence or Presence of Ca ++ 
Percent specific [nH]serotonin release from 
platelets in suspending fluid 
Without Ca  ++  With EDTA  (10  -2 M)  With Ca  ++ 
1st dose*  0  0  8, 6 
2nd dose~  54, 2  63, 8  48 
with Ca  ++ 
I st dose + 
2nd dose after~ 
10 s  47, 8  46, 7  16, 3 
1 min  31, 6  24, 3  9,  1[I 
3min  1, 1  3,8  5,7 H 
5 rain  0  0  8, 2][ 
* Release measured 5 min after addition. 
~: Platelets preincubated for 5 min under the conditions indicated were mixed 
with the 2nd dose, and release was measured 5 min later. 
§ Release measured 5 min after addition of 2nd dose. 
[[ This amount of [3H]serotonin  was already released  by the  1st, low dose of 
hexapeptide. 
at desensitization  against the high dose, the first three subthreshold  doses of hexapep- 
tide cause an increasing desensitization, with a  reproducible short  lag phase up to  15 
s. The fourth dose (1.55  ×  10 -6) that per se has  [~H]serotonin-releasing activity causes 
a  complete  and  instantaneous  desensitization  concomitantly  with  the  rapid  release 
reaction.  This small time-dependent  increase  in  desensitization  at  37°C was  the first 
hint  that  activation  and  deactivation  may  be  separable.  Therefore  a  comparable 
experiment  was  done  at  22°C  with  a  first  dose  of  1.35  ×  10  -6  ml/liter  (Fig.  5). 
Whereas  the parallel  values obtained  at  37°C equal  the data  given in Fig. 4  (lowest 
section),  and  in  general  are  slightly  higher  than  at  22°C,  the  time  dependency  of 
desensitization  at  room  temperature  is  obvious.  The  velocity  of the  [3H]serotonin S.  MEUER, B. ZANKER, U. HADDING, AND D. BITTER-SUERMANN  705 
release at 22°C by the high dose alone is as rapid as at 37°C and complete within 
5s. 
A  recovery from deactivation in a  similar test system as above (first stimulus 5.4 
x  10  -7 ml/liter), but with a time gap to the application of the second, high stimulus 
up to 60 min, was not measurable. But from data obtained in a platelet aggregation 
system  (with  washed  platelets  as  well  as  PRP)  under  comparable  experimental 
conditions, we could demonstrate a  recovery from deactivation by C3a after 2-3 h 
(unpublished results). 
Because activation to secretion by the anaphylatoxic peptides is absolutely Ca  ++ 
dependent, we tested the Ca  ++ dependency of the deactivation process at 37°C.  As 
shown in Table II, hexapeptide induces a  deactivation not only in the presence of 
Ca  ++, but also in the absence of Ca  ++ and in the presence of EDTA (0.01  tool/liter, 
to capture free Ca  ++ released by the platelets). Under the latter conditions, no release 
reaction can be triggered by any dose. Although the deactivation is markedly retarded 
in comparison to a Ca  ++ sufficient system (third column and Fig. 4), it finally reaches 
the maximum level. 
Discussion 
Considerations concerning the regulation of  anaphylatoxin activity in vivo generally 
focused  on  the  cleavage  of C3a  or  C5a  by  fluid-phase  enzymes  such  as  serum- 
carboxypeptidase or other proteases. Inactivation of anaphylatoxins by these enzymes, 
however, occurs within minutes (20), whereas platelet activation by C3a and C5a is 
a process of a few seconds (18). Thus, the ability of anaphylatoxins to stimulate target 
cells in spite of these regulatory processes in vivo is probably maintained by the fact 
that  interaction of anaphylatoxins with platelets, for instance, occurs more rapidly 
than cleavage of these stimuli by their fluid-phase control enzymes. This concept is 
supported by an experiment in which platelets and C3a had been incubated in the 
presence of excess carboxypeptidase B  (8).  Under  these  competitive experimental 
conditions,  C3a  exerted unaltered  biological  activity.  Furthermore, environmental 
conditions at  local inflammatory sites  (low pH)  may protect anaphylatoxins from 
being inactivated rapidly. The function of fluid-phase control, therefore, should be 
considered as preventing a longer persistance and the systemic accumulation of active 
anaphylatoxins  in  vivo and  acting as  a  second-line regulatory mechanism.  If this 
assumption is correct, there should be a cell-associated first-line regulatory mechanism 
to prevent continuous cell activation. 
We conclude from our experiments that regulation of the stimulus-cell interaction 
by the mechanism of specific desensitization, which is located at the target cell level, 
might be responsible for maintaining an essential  balance:  secretion from platelets 
induced by anaphylatoxins occurs only in pathologic but not physiologic situations. 
The results presented in this study suggest that the mechanism of desensitization 
prevents platelets from responding to any low anaphylatoxic stimulus generated in 
their presence. Consequently, platelet reactivity towards preformed anaphylatoxins is 
then reduced. 
It is conceivable that platelets in vivo are constantly desensitized to a certain extent 
as  a  result of C3a  and  C5a  that  are  generated during the physiologic turnover of 
complement. Therefore, a stimulus, to be capable of inducing a secretory event, has 
to fulfill prerequisites of a  "second stimulus," according to Fig.  2. This means that 706  CELLULAR CONTROL  OF ANAPHYLATOXIN ACTIVITY 
platelets could be activated by preformed  anaphylatoxic molecules, provided these 
stimuli occur in concentrations that  are ~50-  100-fold higher than those present in 
the platelets' physiologic environment. 
It is more likely, however, that in vivo an anaphylatoxic stimulus is generated in 
the  vicinity of the  target  cell  so  that  the  concentration of the  stimulus increases 
continuously. Kinetic studies reported here (Fig. 1, Table I) clearly demonstrate that 
secretion  can  occur  only  if the  gradient  of anaphylatoxin concentration is  steep 
enough to exceed a  threshold value within a  critical, very short period of time. 
If the gradient is too gentle, this necessary concentration will not be built up within 
the required interval, and only desensitization ensues. In this situation, a  target cell 
will  no  longer  be  able  to  subsequently respond  to  very  high  concentrations of 
anaphylatoxins with secretion of granule constituents. The accumulated concentra- 
tions of anaphylatoxins, therefore, cannot be correlated to their biologic efficacy in 
vivo. 
This concept is illustrated in Fig. 6.  Induction of desensitization and of secretion 
can be clearly separated  by varying the  steepness of concentration gradient of an 
anaphylatoxic stimulus in the platelets' environment. The process of activation to 
secretion  thus  depends  on  both  concentration  and  time,  whereas  the  degree  of 
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Flo. 6.  Concept  of a stimulus-specific  low-zone  desensitization  as a cell-bound regulatory mecha- 
nism for control of the biological  effects of AT-peptides. Step 1: the majority of the anaphylatoxic 
peptides (AT-peptides) that escape the fluid-phase control interact with reactive platelets (symbol- 
ized by the rough cell surface) and induce a strong release reaction. The resulting platelet with a 
reduced serotonin content  is now unresponsive towards the same stimulus (symbolized by the 
smooth surface). Steps 2 and 3:  the desensitized platelet takes up serotonin again but remains 
desensitized for a certain time and then regains reactivity (step 3). Step 4: a low amount of AT- 
peptides, after passing the fluid-phase control, interacts with reactive platelets but is not able to 
induce a measurable release reaction. Steps 5 and 6: nevertheless,  this platelet is stimulus specifically 
desensitized without any preceeding serotonin release. Again, after a certain time this platelet 
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desensitization is only a function of anaphylatoxin concentration in the vicinity of the 
target  cell. Therefore, it  is  possible to induce C3a-specific unresponsiveness of the 
platelets without a preceeding secretory event by adding the hexapeptide C3a 72-77 
stepwise  to  the samples  (Fig.  3).  The  state of platelet  desensitization is  reversible 
within ~2-3 h  (unpublished results). 
The experiments performed to dissect the process of desensitization from activation 
to secretion yielded positive results by only manipulating the physiological conditions 
of--<37-22°C and by depriviation of Ca  ++  (Fig. 4 and Fig. 5, Table II). The Ca  ++ 
independence seems to be a general feature of desensitization (33, 35), indicating that 
for binding of the ligand to its receptor and for the signal to switch off the secretory 
response there is no need of extracellular Ca  ++. The use of enzyme inhibitors to block 
distinct enzymatic steps  within the chain of signal processing  as well as electron 
microscopic studies on the fate ligand-receptor complexes will give further information 
on the interdependence of desensitization and activation. 
A principally similar phenomenon of specific desensitization has been reported for 
platelets measured as release reactions (18, 32) or as platelet aggregation (33) and for 
neutrophils in their response to anaphylatoxic stimuli (3, 24, 34). Moreover, a state of 
stimulus-specific unresponsiveness has been found in a great number of inflammatory 
cells  (for  review see  ref.  32).  Some  of the  most  interesting  studies  regarding  the 
regulatory function of the phenomenon of low zone desensitization have been per- 
formed with rabbit and human neutrophils and human eosinophils in their response 
to stimuli such as C5a, the peptide Formyl-Methionyl-Leucyl-Phenylalanine (3, 35, 
36), the high molecular weight neutrophils chemotactie factor (HMW-NCF), (37) and 
the  acidic  tetrapeptides  of eosinophil chemotactic  factor  (38,  39).  Similar to  our 
results, these authors demonstrated that desensitization is a  time and concentration- 
dependent process.  Moreover, desensitization could be induced using concentrations 
of stimuli  lower  than  those  required  for  optimum  activation.  In  particular,  the 
reported examples of the tetrapeptides of eosinophil chemotactic factor and of HMW- 
NCF underline that the striking dose-response relationship between deactivating and 
activating concentrations of stimuli, as described in the present paper, are not unique. 
In this context, one might envisage that slowly increasing concentrations of C3a- 
related substances applicated in vivo could induce a selective state of unresponsiveness 
for C3a without exerting secretory activity themselves. This may allow studies of in 
vivo effects of the C3-derived anaphylatoxic polypeptide. Synthetic C3a analogs may 
represent suitable substances for in vivo desensitization because they are C3a specific 
and  they are  not  immunogenic.  Moreover,  the  dose range  between secretory and 
inhibitory effect is considerably greater for the synthetic substances than for C3a itself 
(17). 
The concept of in vivo desensitization by synthetic analogs could be extended to 
C5a as well, which has recently been reported  (23,  40, 41)  to exert severe systemic 
effects in the course of complement activation in vivo. Therefore, the present investi- 
gations  seem  to  have  a  broader  relevance  for  understanding  how  secretory  and 
chemotactic target cells control inflammatory stimuli. 
Summary 
The  biologic  activity of the  anaphylatoxic peptides  C5a  and  C3a  is  regulated 
efficiently at the target-cell level by the phenomenon of desensitization. Desensitiza- 708  CELLULAR CONTROL OF  ANAPHYLATOXIN ACTIVITY 
tion  of platelets  is  stimulus  specific  and  can  be  induced  by low  concentrations  of 
anaphylatoxins  without  any preceeding  secretory event.  In contrast  to activation  to 
secretion,  desensitization  is  Ca  ++  independent  but  much  more  time  consuming, 
especially  at  lower  temperatures  where  both  processes  differ  markedly  in  reaction 
velocity. This low zone desensitization insures that secretion from platelets only occurs 
when  high  amounts  of anaphylatoxins  are  rapidly  generated  in  the  vicinity  of the 
target-cell. Consequently,  stimulus-specific unresponsiveness of the target ceils can be 
induced  by  slowly  increasing  the  concentration  of the  respective  stimuli  in  their 
vicinity. Cellular control seems to act as a  first-line mechanism of regulation, whereas 
the  role  of fluid-phase  control  is  considered  as  preventing  longer  persistance  and 
systemic accumulation  of active anaphylatoxins. 
Note added in proof." After this  manuscript  had  been  submitted,  a  paper by K.  M. 
Skubitz  and  P.  R.  Craddock  was  published  (J.  Clin.  Invest.  67:1383,  1981)  that 
supports our concept  of low-zone deactivation  as a  stimulus-specific  cellular control 
mechanism and demonstrates  its validity under in vivo conditions with C5aamrg and 
human granulocytes. 
The authors wish to thank Ms. Gudrun Thiele for her excellent technical assistance and Dr. H. 
P. Hartung for many helpful discussions. 
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